Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

VIENTIANE: The Indochina Bank has officially launched its latest product, the ‘Daina Pay’, to facilitate transactions including the payment of urgent bills. The bank’s managing director ...

Academy Award-nominated actor John Lithgow is reportedly closing in on a deal to play Headmaster Albus Dumbledore in the upcoming HBO Harry Potter series. Celebrity AI video protests Kanye West ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared ...

Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($1.74) for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68 ...

Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($0.46) for the quarter. The consensus estimate for Fate Therapeutics’ current ...